The newborn screening market offers significant opportunities driven by rising neonatal populations and congenital disease ...

Alteogen inks licensing agreement with Tesaro to develop subcutaneous formulation of dostarlimab enabled by Hybrozyme Technology: Daejeon, South Korea Wednesday, January 21, 2026, ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Complex sugar-protein molecules that sense external messages to help a cell grow or respond to its environment can now be ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered ...

Alteogen and Tesaro, a subsidiary of GSK, have entered an exclusive license agreement concerning a subcutaneous formulation of dostarlimab.

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

While working as an engineer at Tesla, Niccolo Cymbalist never planned to start a business. But he’d been considering an idea ...

Oral presentation to highlight first-ever clinical evidence supporting use of a targeted GYS1 substrate reduction therapy, ...

Let’s say it’s 2036, and scientists are working on a new class of drugs. Today, for instance, pharmaceutical companies use ...

Gregory Gregoriadis, who has died aged 91, pioneered the use of particles known as liposomes for drug targeting and laid the ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...